Drug General Information (ID: DDI87190NE)
Drug Name			Heparin		Drug Info		Cefotetan		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anticoagulants				Antibiotics
Structure

Mechanism of Heparin-Cefotetan Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Heparin				Cefotetan
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Inhibit the growth of vitamin K-producing intestinal bacteria, inhibit the production of vitamin K-dependent coagulation factors via the methylsulfotetrazole side chain, and/or inhibit platelet activity
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Heparin and Cefotetan

Recommended Action
Management		Usually, no special management is necessary, but the patient should be monitored for bleeding if heparin must be given concurrently. Vitamin K is effective in treating cephalosporin-induced coagulopathies.

References
1	Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984): 314-6
2	Joehl RJ, Rasbach DA, Ballard JO, et al "Moxalactam: evaluation of clinical bleeding in patients with abdominal infection." Arch Surg 118 (1983): 1259-61
3	Weitekamp MR, Aber RC "Prolonged bleeding times and bleeding diathesis associated with moxalactam administration." JAMA 249 (1983): 69-71